- Research article
- Open Access
Long-term effects of stimulants on neurocognitive performance of Taiwanese children with attention-deficit/hyperactivity disorder
BMC Psychiatry volume 13, Article number: 330 (2013)
Attention-deficit/hyperactivity disorder (ADHD) is a common behavioral and neurocognitive disorder in school-age children. Methylphenidate (MPH) is the most frequently prescribed CNS stimulant for ADHD. The aim of this study is to evaluate the changes in intelligence quotient and domains of neurocognitive function after long-term MPH treatment of Taiwanese children with ADHD.
The Wechsler Intelligence Scale (WISC-III) was administrated twice at an interval of at least one year for all 171 subjects (6–12 years) and 47 age- and gender-matched children without ADHD. The ADHD-Rating scale and Clinical Global Impression-Severity (CGI-S) were also used at the time of enrolment, and at 6 months and one year later.
Taiwanese children with ADHD had lower Verbal IQ (VIQ) and Full IQ (FIQ) and performed poorly on several subtests of the WISC-III, including Similarities, Vocabulary, and Coding, compared to healthy children without ADHD. After one year of MPH treatment, significant decrements in all scores of the ADHD-Rating scale and CGI-S and increments in several domains of the WISC-III, including FIQ, VIQ, PIQ, Perceptual Organization Index (POI), Picture Completion, Picture Arrangement, Object Assembly, and Digit Span were observed. When the ADHD children under MPH treatment were subdivided into two age groups (6–8 years and 9–12 years), significantly better performance in some subtests and subscales of the WISC-III (such as Similarities, Comprehension, and Object assembly) was found in the 6–8 years age group.
Long-term MPH treatment may improve the neurocognitive profiles of the ADHD children, as seen in their performance in several subtests and in the IQ scores on the WISC-III. And this improvement had no correlation with the decrement of ADHD symptoms. Starting stimulant treatment at as young an age as possible is advised due to the greater benefits in the 6–8 years age group, as seen in this study. More research in this area is also needed to confirm these results.
Attention deficit hyperactivity (ADHD), one of the most common behavioral and neurocognitive disorders , is characterized by persistent over activity, inattention and impulsivity. The American Psychiatric Association (APA, 1994) diagnostic guideline [Diagnostic and Statistical Manual, version IV (DSM-IV)] classified ADHD into three subtypes: (a) inattentive, (b) hyperactive–impulsive and (c) combined. According to the DSM-IV, text version (DSM-IV-TR) diagnostic guidelines, the prevalence of ADHD is estimated at 3–7% in school-age children [2, 3]. Due to the nature of the populations sampled, diagnostic criteria used, cultural differences, and methodological limitations, the prevalence of ADHD in various cultures varies. The prevalence is estimated to be about 8.4–11.7% in Taiwan ; 2.4% in Australia ; and 4% in Japan . The negative outcomes of ADHD include peer rejection, low self-esteem, academic underachievement, and learning disabilities [7, 8]. Cognitive function impairment as in executive dysfunction and a lower intellectual coefficient were also found in ADHD children. Although the concept of executive function is broad and variable, overall it is used in reference to the higher brain process involved in planning problem-solving and can be screened using the Wechsler Intelligence Scale (WISC) . From the intellectual coefficient perspective, a meta-analytic review by Frazier et al. reported that the ADHD groups performed at an average of 9.15 points lower than the control group in their Full Scale Intelligence Quotient (FSIQ), assuming a theoretical standard deviation of 15 .
Methylphenidate (MPH), a kind of central nervous system (CNS) stimulant, is the most frequently prescribed medication for ADHD, and its clinical efficacy is well established . The effects of MPH on attention result from a combination of noradrenergic and dopaminergic mechanisms , which are assumed to ameliorate the two principal problems of attention deficiency and impulsivity/hyperactivity in children with ADHD. Moreover, scholars hypothesized that treating ADHD symptoms via stimulant drugs not only decreased the negative impact of ADHD, but possibly also benefited the neurocognitive performances of children with ADHD . A previous meta-analysis by Kavale et al. found that stimulant treatment for an average period of 18 weeks led to a mean gain of about 6 to 7 points in FSIQ, and 6 points in both the Verbal Intelligence Quotient (VIQ) and Performance Intelligence Quotient (PIQ) . Another meta-analysis by Thurber and Walker  also demonstrated that short-term stimulant drug effects could result in a mean increase of 2.25 points in the FSIQ. Recent studies that focus on intellectual outcomes after a long-term treatment period have shown that long-term stimulant treatment for at least one year could increase the Intelligence Quotient (IQ) score in children with ADHD, and that more improvement in IQ scores was found in the group of those who could maintain a longer treatment duration [16, 17]. That is, the intellectual performance of children with ADHD may be improved with long-term CNS stimulant treatment, as well as short-term stimulant treatment, but a bigger gain with long-term treatment is suspected. In addition to the decreased severity of core symptoms, avoidance of negative consequences and improved neurocognitive performances of children with ADHD, MPH has been shown to counteract the detrimental effects of earlier-origin developmental insults  and has age-dependent effects on prefrontal neurons [19, 20]. So it is also suspected that starting drug treatment at an earlier age may have more benefits.
In Taiwan, a high prevalence rate of ADHD was noticed about ten years ago , but there is still little research comparing neurocognitive function between children with ADHD and healthy children. And even though the positive effect of CNS stimulants in ADHD treatment has been reported in many studies, there are still few studies examining the long-term effect of CNS stimulants on neurocognitive function and in different age groups. Therefore, in this study, we have several objectives as below: 1) to better understand the neurocognitive performance of ADHD children in Taiwan as measured by the WISC-III and to further compare the results with healthy controls; 2) to investigate the changes in rating scale and IQ and the influences on the domains of the WISC subtests after long-term MPH treatment in Taiwanese children with ADHD; 3) to explore if there is more benefit to long-term MPH treatment; and 4) to know if MPH treatment has a diverse effect on neurocognitive profiles in different age groups.
We collected ADHD children from the outpatient clinics of a medical center in northern Taiwan from December 2005 to 2006. Inclusion criteria were: age 6–12 years; and a clinical diagnosis of ADHD based on the relevant DSM-IV diagnostic criteria and standardized clinical assessments, as determined by experienced board-certificated child psychiatrists. Study approval was obtained from the Institutional Review Board of Chang Gung Memorial Hospital. Written informed consent was obtained from the parents of each child and children following an explanation of the study.
The diagnostic assessment of ADHD were performed by two senior child psychiatrists, who administered structured interviews using the Chinese-language version of the Schedule for Affective Disorder and Schizophrenia for School-Age Children , epidemiologic version (K-SADS-E) . This evaluation affirmed the clinical diagnosis and excluded children who had co-morbid pervasive developmental disorder, or a history of bipolar disorder, psychosis, anxiety disorder, seizure disorder, substance abuse or mental retardation. Other physical and neurological examinations were performed by a pediatrician and neurologist to rule out CNS or other physical diseases. All ADHD children enrolled in this study were drug-naïve at baseline. Treatment involved administering 0.3-7 mg/kg/dose of MPH to all subjects, which was within the range of the average daily dose in Taiwan .
Since executive function could be screened by the WISC , we chose this psychometric measurement to evaluate the neurocognitive performance of ADHD and healthy children. After the initial screening, all the eligible children were administered the WISC-III  by experienced child psychologists. The ADHD-Rating scale  and Clinical Global Impression-Severity (CGI-S)  were also scored simultaneously by an experienced child psychiatrist.
The WISC-III is a standardized intelligence test suitable for children and adolescents aged 6–16 years. It contains 13 subtests, namely Information, Similarities, Arithmetic, Vocabulary, Comprehension, Digit Span, Picture Completion, Coding, Picture Arrangement, Block Design, Object Assembly, Symbol Search and Maze. VIQ, PIQ and full IQ (FIQ), and their scores can be calculated based on these subtests. The verbal comprehension index (VCI), perceptual organization index (POI), freedom from distractibility index (FDI), and processing speed index (PSI) were also calculated from these subtests. The WISC-III was used when the participants first enrolled in the study. Repeated WISC-III tests were administered for those who stayed in the study and received CNS stimulant treatment for one year. The second WISC-III test was administered at least one year from the first test. All participants were free from medication for at least one week prior to the first and the second administration of the WISC-III.
The ADHD-Rating scale is a structured interview completed by the investigator based on information from the parents and child. Each of the items has a 4-point response scale, and each item explores one of the 18 criteria outlined in the DSM-IV to diagnose ADHD. Higher scores indicate greater severity of ADHD. Initial evaluation was scored when the ADHD children were enrolled, and again at 6 months and one year into treatment.
The CGI-S uses a 7-point scale with responses ranging from 1 (normal) to 7 (the most severely ill patients). The scale was filled out at initial intake, and at 6 months and one year into the study, coinciding with the administration of the ADHD-Rating scale.
To compare the differences between healthy children without ADHD and children with ADHD in their performance on the intelligence test, we recruited 47 age-matched children (6–12 years) from surrounding schools in the community by contacting the teachers. Inclusion criteria included healthy children, as reported by the parents, and the absence of ADHD symptoms. All children in the control group were evaluated at the “child developmental evaluation center” of the hospital, where physical, neurological and mental evaluations were performed by the same specialists that saw the suspected ADHD children. The exclusion criteria for the control group were the same as those for the ADHD group.
The variables of sample characteristics, scores on the ADHD-Rating scale and CGI-S, and profiles of neurocognitve performance evaluated via the WISC-III between the healthy normal controls and the ADHD children were compared using two sample t-tests and the chi-square test. The changes in the ADHD-rating scale and CGI-S and in performances on the WISC-III before and after MPH treatment in the ADHD group were compared using the paired t-test. The correlation between the changes in the severity of ADHD symptoms and performance on the WISC-III was analyzed via Pearson's correlation coefficient. All tests were performed using SPSS 15.0, with a 2-tailed significance level of 0.05.
A total of 171 children with ADHD were included in our study.
Differences in the neurocognitive performance of ADHD and healthy normal children
Compared to the healthy children, the ADHD children had significant differences in their scores on the ADHD-Rating scale (Table 1), including inattention (p < 0.001), hyperactivity (p < 0.001) and total (p < 0.001) scores, and on the CGI-S (p < 0.001). Children with ADHD also scored significantly worse than children in the control group in FIQ (p < 0.05), VIQ (p < 0.05) and several subtests of the WISC-III, including Similarities (p < 0.01), Vocabulary (p < 0.05), Coding (p < 0.05) and VCI (p < 0.05).
Differences between ADHD children who received stimulant drugs or not
Of the 171 ADHD children, 130 received MPH treatment. The 41 ADHD children without MPH treatment were younger (p < 0.01) and had less severity on the ADHD-Rating scale, including hyperactivity (p < 0.01) and total (p < 0.05) scores and on the CGI-S (p < 0.01), than those under MPH treatment. However, there was no significant difference in performance on the WISC-III between these two groups.
Difference within drug treatment groups between those who received MPH beyond one year and those who were lost to follow-up
In the MPH treatment group, 103 participants (79%) continued in the study beyond one year. Children who were lost to follow-up during the period of MPH treatment had the same severity of ADHD symptoms, but had better performance in FIQ (p < 0.05), VIQ (p < 0.05), PIQ (p < 0.05), Arithmetic (p < 0.01), and Vocabulary (p < 0.001).
Changes in neurocognitive function after long-term MPH treatment
The 103 participants who stayed in the study beyond one year were administered the ADHD-Rating scale and the CGI-S at 6 months and one year. Psychometric measures using the WISC-III were also completed for the 103 participants again at the end of one year. All subscores on the ADHD-Rating scale, including inattention (p < 0.001), hyperactivity (p < 0.001) and total (p < 0.001), and the CGI-S (p < 0.001) decreased significantly for ADHD children after drug therapy. Significant increments in the FIQ (p < 0.001), VIQ (p < 0.05) and PIQ (p < 0.001) scores were also found in the MPH treatment group. Among the subtests of the WISC-III, significant improvements in performance were found in Picture Completion (p < 0.01), Picture Arrangement (p < 0.01), Object Assembly (p < 0.05), and Digit Span (p < 0.05). The POI (p < 0.001) score also improved significantly after drug therapy (Table 2).
Differences in the changes in neurocognitive function after long-term MPH treatment among the ADHD children with or without learning disorders
ADHD is often comorbid with learning disorders (LD), which would influence performance on the WISC-III. We subdivided the ADHD children with MPH treatment into two groups. One group included 19 ADHD children comorbid with LD and the other, ADHD children without LD. However, we did not find a significant difference between the two groups in the changes in ADHD symptoms and in the WISC-III after MPH treatment.
Changes in neurocognitive function of ADHD children with/without MPH treatment at the end of one year
We compared the differences between ADHD children with/without MPH treatment for one year. The results showed that there was a significant increase in FIQ (p < 0.001), VIQ (p < 0.05), PIQ (p < 0.001), Picture completion (p < 0.001), Picture arrangement (p < 0.01), Object assembly (p < 0.05), Digit span (p < 0.05) and POI (p < 0.001) among the ADHD children who received MPH treatment. However, there were no significant changes in performance on the WISC-III among the ADHD children not receiving MPH treatment. The sample size of the ADHD children who received and did not receive MPH treatment was 103 and 17, respectively.
Effect of MPH treatment on neurocognitive profiles in different age groups
The ADHD children under MPH treatment were subdivided into two age groups (6–8 years and 9–12 years). The pre-treatment data of the 6–8 years age group were found to be significantly higher in inattention (p < 0.01), hyperactivity (p < 0.05), and total scores (p < 0.01) on the ADHD-rating scale and CGI-S (p < 0.01), and significantly lower on the Similarities subtest of the WISC-III (p < 0.01) (Table 3). After one year of MPH treatment, there were significant decrements in severity of ADHD symptoms in both age groups, but without a statistically significant difference in the range of improvement of the two groups (Table 4). Significant improvements in Similarities (p < 0.05), Picture Completion (p < 0.05), Object Assembly (p < 0.01), FIQ (p < 0.01), and POI (p < 0.05) were noted in the 6–8 years age group, and significant improvements in Picture Completion (p < 0.05), Picture Arrangement (p < 0.01), FIQ (p < 0.05), PIQ (p < 0.01) and POI (p < 0.01) were noted in the 9–12 years age group. However, the Comprehension subtest score decreased significantly in the 9–12 years age group (p < 0.05) after MPH treatment. When comparing the range of changes in the WISC-III across these two age groups, more improvement with statistical significance in the performances of Similarities (p < 0.05), Comprehension (p < 0.05) and Object Assembly (p < 0.05) were found in 6–8 years age group after one year of MPH treatment. Based on these results, more benefit from receiving MPH treatment could be found in the younger age group (6–8 years) than in the older age group (9–12 years).
Effect of MPH treatment on neurocognitive profiles in different age groups of ADHD children with or without LD
When further subdividing the group of ADHD children under MPH treatment comorbid with or without LD into two age groups (6–8 years and 9–12 years), similar results could be noted. More improvement with statistical significance in the performances of Similarities (p < 0.01), Comprehension (p < 0.05) and Object Assembly (p < 0.05) was found in 6–8 years age group.
Correlation between the changes in neurocognitive profiles and severity of ADHD symptoms
No significant correlation was found between the changes in performance on the WISC-III (including 13 subtests, VCI, POI, FDI, PSI, FIQ, VIQ, and PIQ) and the severity of ADHD symptoms as measured by the ADHD-Rating scale and CGI-S (Table 5).
Correlation between the changes in neurocognitive profiles and baseline severity of ADHD symptoms
Similarly, there were no significant associations between the changes of WISC-III and the baseline ADHD severity and CGI scores in the MPH treatment group (Table 6).
In this study, children with ADHD had lower VIQ and FIQ than healthy children without ADHD. The findings in this study showed that FIQ was approximately 9 points lower in children with ADHD than in healthy children. This is compatible with the results of a previous meta-analytic review, which reported that ADHD groups performed at an average of 9.15 FIQ points lower than the control group . We also found that children with ADHD performed poorly on several subtests of the WISC-III, including Similarities, Vocabulary, and Coding, compared to healthy children. The finding that children with ADHD perform poorly in Coding is consistent with several studies [27–30]. However, there continues to be incongruence in the profile of other WISC-III subtests for children with ADHD. A previous study  revealed lower scores in Picture Arrangement, Block Design, and Object Assembly in ADHD groups. But their sample size of 26 control participants and 35 children with ADHD was relatively small. Since their study had limited data and various methodological differences from our study, comparing our results would result in inconsistencies.
The benefits to cognitive function after MPH treatment were noted in many studies [31–34], but there is sparse research and incongruent results in the area of the effect of MPH on subtests of the intelligence test. For example, the ADHD children's improvement on several WISC-III subtests after drug treatment in this study was incompatible with the results of another study that found a positive effect of MPH on the verbal comprehension index . Therefore, the potential influence of MPH on the performance of ADHD children on the WISC-III, except for the IQ scores, needs further research.
There are no recommendations regarding the optimal period for ADHD drug treatment. According to the results of this study, the degree of improvement in ADHD symptom severity was not significantly different relative to the patient's age on receiving MPH treatment. On the other hand, significantly better performance in some subtests and subscales of the WISC-III (such as Similarities, Comprehension, and Object Assembly) was noted in the 6–8 years age group. This suggests that it would be best to start MPH treatment for ADHD at a younger age. However, previous studies have not found that younger age groups obtained more benefits in various aspects than older age groups as a result of MPH treatment. Thus, more research is needed to corroborate this finding and to reach a conclusion.
It has been hypothesized that attention deficit in ADHD children would substantially influence IQ , so improving attention would secondarily improve IQ scores. However, this hypothesis was not supported by previous studies, which revealed no significant correlation between the severity of ADHD symptoms and WISC-III IQ scores [36, 37]. In addition, the hypothesis that improving attention would secondarily improve IQ scores has also been refuted. Several studies found that improvements in behavioral symptoms had no correlation with changes in cognitive parameters [35, 38, 39]. This is also consistent with our results that no association was found between improvements in ADHD symptoms and changes in the scores of the WISC-III subtests and subscales (i.e., VCI, POI, FDI, PSI, FIQ, VIQ, and PIQ). It seems that the better performance on intelligence tests after MPH treatment did not result from lessening ADHD symptoms. MPH may possibly produce a different benefit and utilize another mechanism of improving performance on the WISC-III, aside from ameliorating suboptimal test-taking behavior in ADHD children. But MPH may not actually improve construct of IQ as much as it just improves accuracy on the test due to improved attention should be kept in mind.
There are several limitations in this study. First, the sample enrolled in the study did not include all patients with ADHD, so the findings might not be applicable to the entire population of ADHD patients. Second, the sample size in the study was relatively small, particularly for the control group, and some WISC-III subtests (i.e., Symbol Search and Digit Span) were not administered to the control group. Therefore, the statistical power in this study was limited in its ability to detect the changes from pre- to post-treatment and the differences between ADHD and healthy children. Large-scale studies using integrated psychometric measurements are needed. Third, the majority of children with ADHD were male, so the influence of sex could not be ruled out. Fourth, this was not a randomized controlled trial and whether to start MPH treatment or not was based on clinical evaluation and most importantly the opinions of the parents of the ADHD children. Fifth, the interval between the 1st and 2nd administration of the WISC-III was not long enough to ignore the practical effect without controversy. Sixth, other treatments (i.e., cognitive behavioral therapy, parental training, attention training) associated with MPH treatment were often performed in clinical practice, but the interactions and their possible effect on the WISC-III was not followed up in this study.
Although many limitations have been noted, a number of strengths can also be found in this study. First, real-world children with ADHD were sampled and given an appropriate dose of MPH in line with clinical guidelines. Second, the 1st and 2nd administration of the WISC-III was given at least one year apart, thus reducing the possible practical effect to a limited degree [24, 40]. Although the sample size of ADHD children with/without MPH treatment was small in this study, the practical effect could not totally explain the improvement in the WISC-III after MPH treatment, because there were no significant changes in the ADHD children who did not receive MPH treatment after one year. Third, all participants were free from medication for at least one week before performing the WISC-III, which would reduce the direct influence of medication on improving test-taking behavior. Thus, the present study is valuable because of its strengths.
According to the findings in this study, we suggest that long-term MPH treatment may improve neurocognitive profiles, which were shown in the performance of the ADHD children on several subtests and in IQ scores of the WISC-III. And the improvement had no correlation with the decrement of ADHD symptoms and baseline ADHD severity. Starting stimulant treatment at as young an age as possible is advised due to the greater benefits seen in the 6–8 years age group. But more research using a controlled sample to replicate the findings is needed.
Spencer TJ, Biederman J, Mick E: Attention-deficit/hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology. J Pediatr Psychol. 2007, 32: 631-642. 10.1093/jpepsy/jsm005.
APA: Diagnostic and statistical manual of mental disorders, DSM-IV-TR (text revision). 2000, Washington, DC: American Psychiatric Association, 4
Barkley RA: Attention-deficit hyperactivity disorder: a handbook for diagnosis and treatment. 1998, New York: Guilford, 2
Tzang R-F, Wu K-H, Liou C-P: Prevalence of attention-deficit/hyperactivity disorder in a Taiwanese elementary school. Taiwanese J Psychiatry. 2002, 16: 202-212.
Gomez R, Harvey J, Quick C, Scharer I, Harris G: DSM-IV AD/HD: confirmatory factor models, prevalence, and gender and age differences based on parent and teacher ratings of Australian primary school children. J Child Psychol Psychiatry. 1999, 40: 265-274. 10.1111/1469-7610.00440.
Robison LM, Sclar DA, Skaer TL, Galin RS: National trends in the prevalence of attention-deficit/hyperactivity disorder and the prescribing of methylphenidate among school-age children: 1990–1995. Clin Pediatr (Phila). 1999, 38: 209-217. 10.1177/000992289903800402.
Barkley RA, DuPaul GJ, McMurray MB: Comprehensive evaluation of attention deficit disorder with and without hyperactivity as defined by research criteria. J Consult Clin Psychol. 1990, 58: 775-789.
Steele M, Jensen PS, Quinn DM: Remission versus response as the goal of therapy in ADHD: a new standard for the field?. Clin Ther. 2006, 28: 1892-1908. 10.1016/j.clinthera.2006.11.006.
Zambrano-Sanchez E, Martinez-Cortes JA, Rio-Carlos YD, Martinez-Wbaldo Mdel C, Poblano A: Executive dysfunction screening and intelectual coefficient measurement in children with attention deficit hyperactivity disorder. Arq Neuropsiquiatr. 2010, 68: 545-549. 10.1590/S0004-282X2010000400013.
Frazier TW, Demaree HA, Youngstrom EA: Meta-analysis of intellectual and neuropsychological test performance in attention-deficit/hyperactivity disorder. Neuropsychology. 2004, 18: 543-555.
Zarin DA, Suarez AP, Pincus HA, Kupersanin E, Zito JM: Clinical and treatment characteristics of children with attention-deficit/hyperactivity disorder in psychiatric practice. J Am Acad Child Adolesc Psychiatry. 1998, 37: 1262-1270. 10.1097/00004583-199812000-00009.
Overtoom CCE, Verbaten MN, Kemner C, Kenemans JL, Engeland H, Buitelaar JK, van der Molen MW, van der Gugten J, Westenberg H, Maes RAA, et al: Effects of methylphenidate, desipramine, and l-dopa on attention and inhibition in children with attention deficit hyperactivity disorder. Behav Brain Res. 2003, 145: 7-15. 10.1016/S0166-4328(03)00097-4.
Jepsen JR, Fagerlund B, Mortensen EL: Do attention deficits influence IQ assessment in children and adolescents with ADHD?. J Atten Disord. 2009, 12: 551-562. 10.1177/1087054708322996.
Kavale K: The efficacy of stimulant drug treatment for hyperactivity: a meta-analysis. J Learn Disabil. 1982, 15: 280-289. 10.1177/002221948201500508.
Thurber S, Walker CE: Medication and hyperactivity: a meta-analysis. J Gen Psychol. 1983, 108: 79-86. 10.1080/00221309.1983.9711481.
Gillberg C, Melander H, von Knorring AL, Janols LO, Thernlund G, Hagglof B, Eidevall-Wallin L, Gustafsson P, Kopp S: Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. A randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1997, 54: 857-864. 10.1001/archpsyc.1997.01830210105014.
Gimpel GA, Collett BR, Veeder MA, Gifford JA, Sneddon P, Bushman B, Hughes K, Odell JD: Effects of stimulant medication on cognitive performance of children with ADHD. Clin Pediatr (Phila). 2005, 44: 405-411. 10.1177/000992280504400504.
Marco EM, Macri S, Laviola G: Critical age windows for neurodevelopmental psychiatric disorders: evidence from animal models. Neurotox Res. 2011, 19: 286-307. 10.1007/s12640-010-9205-z.
Urban KR, Waterhouse BD, Gao WJ: Distinct age-dependent effects of methylphenidate on developing and adult prefrontal neurons. Biol Psychiatry. 2012, 72: 880-888. 10.1016/j.biopsych.2012.04.018.
Gronier B, Aston J, Liauzun C, Zetterstrom T: Age-dependent effects of methylphenidate in the prefrontal cortex: evidence from electrophysiological and Arc gene expression measurements. J Psychopharmacol. 2010, 24: 1819-1827. 10.1177/0269881109359100.
Gau S-F, Suen Soong W-T: Psychiatric comorbidity of adolescents with sleep terrors or sleepwalking: a case–control study. Aust N Z J Psychiatry. 1999, 33: 734-739. 10.1080/j.1440-1614.1999.00610.x.
Chong M-Y, Chan K-W, Cheng ATA: Substance use disorders among adolescents in Taiwan: prevalence, sociodemographic correlates and psychiatric co-morbidity. Psychol Med. 1999, 29: 1387-1396. 10.1017/S0033291799001257.
Gau S-F, Chiu Y-N, Tsai W-C, Soong W-T: Average daily dose of methylphenidate for children with attention-deficit hyperactivity disorder in a medical center. Taiwanese J Psychiatry. 2004, 18: 136-141.
Wechsler D: Manual for the Wechsler intelligence scale for children (Chinese version). 1991, San Antonio, TX: The Psychological Corporation, 3
Faries DE, Yalcin I, Harder D, Heiligenstein JH: Validation of the ADHD rating scale as a clirlician administered and scored instrument. J Atten Disord. 2001, 5: 107-115. 10.1177/108705470100500204.
Guy W: ECDEU assessment manual for psychopharmacology. 1976, Rockville, MD: U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs
Mayes SD, Calhoun SL: Similarities and differences in Wechsler intelligence scale for children–third edition (WISC-III) profiles: support for subtest analysis in clinical referrals. Clin Neuropsychol. 2004, 18: 559-572. 10.1080/13854040490888530.
Filippatou DN, Livaniou EA: Comorbidity and WISC-III profiles of Greek children with attention deficit hyperactivity disorder, learning disabilities, and language disorders. Psychol Rep. 2005, 97: 485-504.
Snow JB, Sapp GL: WISC-III subtest patterns of ADHD and normal samples. Psychol Rep. 2000, 87: 759-765.
Mayes SD, Calhoun SL: WISC-IV and WISC-III profiles in children with ADHD. J Atten Disord. 2006, 9: 486-493. 10.1177/1087054705283616.
Swanson J, Baler RD, Volkow ND: Understanding the effects of stimulant medications on cognition in individuals with attention-deficit hyperactivity disorder: a decade of progress. Neuropsychopharmacology. 2011, 36: 207-226. 10.1038/npp.2010.160.
Hale JB, Reddy LA, Semrud-Clikeman M, Hain LA, Whitaker J, Morley J, Lawrence K, Smith A, Jones N: Executive impairment determines ADHD medication response: implications for academic achievement. J Learn Disabil. 2011, 44: 196-212. 10.1177/0022219410391191.
Kubas HA, Backenson EM, Wilcox G, Piercy JC, Hale JB: The effects of methylphenidate on cognitive function in children with attention-deficit/hyperactivity disorder. Postgrad Med. 2012, 124: 33-48.
Pasini A, Sinibaldi L, Paloscia C, Douzgou S, Pitzianti MB, Romeo E, Curatolo P, Pizzuti A: Neurocognitive effects of methylphenidate on ADHD children with different DAT genotypes: A longitudinal open label trial. Eur J Paediatr Neurol. 2013, 17: 407-414. 10.1016/j.ejpn.2013.02.002.
Hellwig-Brida S, Daseking M, Keller F, Petermann F, Goldbeck L: Effects of methylphenidate on intelligence and attention components in boys with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2011, 21: 245-253. 10.1089/cap.2010.0041.
Naglieri JA, Goldstein S, Delauder BY, Schwebach A: Relationships between the WISC-III and the cognitive assessment system with Conners’ rating scales and continuous performance tests. Arch Clin Neuropsychol. 2005, 20: 385-401. 10.1016/j.acn.2004.09.008.
Schuck SE, Crinella FM: Why children with ADHD do not have low IQs. J Learn Disabil. 2005, 38: 262-280. 10.1177/00222194050380030701.
Coghill DR, Rhodes SM, Matthews K: The neuropsychological effects of chronic methylphenidate on drug-naive boys with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2007, 62: 954-962. 10.1016/j.biopsych.2006.12.030.
Konrad K, Gunther T, Heinzel-Gutenbrunner M, Herpertz-Dahlmann B: Clinical evaluation of subjective and objective changes in motor activity and attention in children with attention-deficit/hyperactivity disorder in a double-blind methylphenidate trial. J Child Adolesc Psychopharmacol. 2005, 15: 180-190. 10.1089/cap.2005.15.180.
Tang S-C, Chen M-Y, Chen C-T: The test-retest stability of the Wechsler intelligence scale for children-third edition. Arch Clin Psychol. 2005, 2: 41-48.
The pre-publication history for this paper can be accessed here:http://0-www.biomedcentral.com.brum.beds.ac.uk/1471-244X/13/330/prepub
Our appreciation is extended to Drs Shur-Fen Gau and Wei-Tsuen Soong for granting us permission to use the Chinese K-SADS-E in this study. Our deepest gratitude goes to all the children and their parents who made this project possible by sharing their experiences with us.
The authors declared that they had no competing interests and received no financial support for this study.
CST, YSH, KBY, MHT and SMC conceived, designed and participated in the study. CLW and FMH analyzed the data and assisted in result interpretation. All authors read and approved the final manuscript.
About this article
Cite this article
Tsai, CS., Huang, YS., Wu, CL. et al. Long-term effects of stimulants on neurocognitive performance of Taiwanese children with attention-deficit/hyperactivity disorder. BMC Psychiatry 13, 330 (2013). https://0-doi-org.brum.beds.ac.uk/10.1186/1471-244X-13-330
- Attention-deficit/hyperactivity disorder